In Q1 2024, Deep Track Capital held 55 positions worth $3.3B. They initiated 18 new positions and exited 32. Their largest holding was SWTX ($171.3M). Portfolio value grew +38.0% versus the prior quarter.
Frequently asked questions
What stocks did Deep Track Capital own in Q1 2024?
Deep Track Capital held 55 biotech stocks in their 13F portfolio in Q1 2024. Their top positions include SWTX, AMGN, APGE, INSM, DYN. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deep Track Capital's portfolio worth in Q1 2024?
Deep Track Capital's tracked biotech portfolio was worth $3.3B across 55 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
What did Deep Track Capital buy in Q1 2024?
Deep Track Capital initiated 18 new positions in Q1 2024, including AMGN, ALNY, MNMD, APLS, VRNA and 13 more. They also increased 14 existing positions.
What did Deep Track Capital sell in Q1 2024?
Deep Track Capital fully exited 32 positions in Q1 2024, including QURE, NKTX, EXEL, DCPH, BIIB and 27 more. They also trimmed 11 existing positions.
Is Deep Track Capital a biotech fund?
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Want AI analysis, insider signals, and catalyst overlays for Deep Track Capital?
View latest Deep Track Capital portfolio →